Core Viewpoint - Aishalon Medical Technology Group Co., Ltd. successfully went public on the Beijing Stock Exchange, marking it as the first new A-share listed company in Jiangsu Province and Suzhou City in 2026, with a focus on stable operational and financial foundations rather than high-risk narratives [1] Company Introduction - Established in 2015 and headquartered in Suzhou, Jiangsu, Aishalon specializes in medical dressings and surgical infection control products, focusing on rehabilitation care and surgical infection control products [5] - The company primarily operates through OEM/ODM models, providing contract manufacturing services for large international medical device companies, with exports to North America, Europe, and South Korea [5] Product and Business Structure - Aishalon's main revenue comes from medical dressing products, particularly care pads, which constitute a significant portion of its overall income [6] - The company has established a comprehensive system covering R&D, production, and quality control, holding ISO 13485 certification and approvals from CE and the US FDA, ensuring stable access to international markets [10] - Aishalon has long-term partnerships with major international medical supply groups like Medline, resulting in stable order flows but also presenting a degree of customer concentration risk [10] Financial Performance - The company has shown steady operational performance, with both revenue and profit experiencing positive growth [11] - Revenue figures indicate a scale of approximately 600-700 million yuan, with continued growth expected post-2024, reflecting strong order and delivery stability [13] - Specific revenue data includes: - 2022: Approximately 573 million yuan - 2023: Approximately 619 million yuan - 2024: Approximately 703 million yuan - 2025 (Jan-Sep): 690 million yuan, a year-on-year increase of 42.84% [15] - Net profit figures are as follows: - 2022: 62.8 million yuan - 2023: 66.9 million yuan - 2024: 80.6 million yuan - 2025 (Jan-Sep): 49.4 million yuan [15][21] - The net profit margin has remained around 11%, indicating a relatively healthy profitability level among medical consumables companies, with profits primarily derived from core operations [16] - As of September 2025, total assets were approximately 1.279 billion yuan, with owner’s equity around 821 million yuan, maintaining a controllable debt ratio and a relatively stable financial structure [17] Industry Observation - Aishalon's listing highlights a path for non-"star innovative device" medical companies to capitalize in a rational capital market environment, providing a clear capitalization model [18] - The continuous entry of such companies into the Beijing Stock Exchange aids in transitioning the medical sector from "single-point innovation" to a coexistence of "multiple types of medical companies" [18] - The emphasis on stable operational capabilities is underscored as a scarce asset within the industry [18]

Core Insights - Aishalon Medical Technology Group Co., Ltd. officially listed on the Beijing Stock Exchange on January 21, 2026, becoming the first A-share listed company in Jiangsu Province this year and the first in Suzhou's Xiangcheng District [2] - The company's stock opened with a significant increase of 224.78%, reaching a total market capitalization of 3.49 billion yuan [2] Company Overview - Aishalon Medical focuses on the research, production, and sales of disposable medical consumables in the fields of rehabilitation care and surgical infection control [3] - The company has established long-term strategic partnerships with several international medical device brands, including Medline Group from the U.S., Zarys Group from Poland, and Sejong Healthcare from South Korea [3] - Aishalon is recognized as the largest manufacturer of medical care pads in China, with annual output value exceeding 500 million yuan from 2022 to 2024, positioning itself among the top players in the domestic medical dressing industry [3] Financial Performance - From 2022 to 2024, Aishalon's operating revenue grew from 574 million yuan to 692 million yuan, while net profit increased from 63 million yuan to 81 million yuan, demonstrating a steady compound annual growth rate [4] - For the first nine months of 2025, the company achieved an operating revenue of 689 million yuan, a year-on-year increase of 42.84%, and a net profit of 73 million yuan, up 27.50% from the previous year [4] - The company has maintained a high proportion of overseas sales revenue, which reached 96.54% in the first half of 2025, indicating its strong role in the global supply chain [4] Industry Context - The medical dressing industry is characterized by rigid demand, driven by global aging populations, increasing surgical volumes, and heightened infection control awareness [5] - The market for medical dressings is expected to continue growing steadily, with a trend towards high-quality, multifunctional, and disposable products [5] Growth Strategy - Aishalon plans to use the funds raised from its IPO to invest in the "Kaipule Public Health Medical Supplies Industrial Park" project, aimed at expanding production capacity and developing new product lines [6] - The company is transitioning from a single dressing production focus to a broader medical consumables manufacturing and service platform, which is expected to reduce dependency on single products and clients [6] - Aishalon is also expanding its global production footprint, with existing bases in Thailand and plans for new facilities in Morocco, showcasing its strategic vision to adapt to international trade dynamics and cost pressures [6]

Core Viewpoint - The electronic sector in the A-share market has experienced a significant surge, with many stocks hitting the daily limit up, indicating strong investor interest and potential growth in this industry [1][6]. A-Share Market Performance - The A-share market showed an overall upward trend, with major indices rising to varying degrees. The ChiNext Index rose over 1.5%, and the Sci-Tech 50 Index increased by more than 4% [4]. - Specific indices and their performance include: - Shanghai Composite Index: 4120.10, up 0.16% [5] - Shenzhen Component Index: 14263.20, up 0.76% [5] - ChiNext Index: 3306.00, up 0.85% [5] Electronic Sector Highlights - The electronic sector led the market with a rise of over 2.8%, with several stocks reaching their daily limit up. Notable performers include: - Longxin Zhongke: 177.72, up 20% [7] - Zhongrong Electric: 143.40, up 20% [7] - Other stocks like Jiahua Technology and Jianghua Microelectronics also saw significant gains [6]. Lithium Mining Sector - The lithium mining sector experienced a substantial increase, with the sector rising over 2%. Stocks such as Dazhong Mining and Weicheng Mining hit their daily limit up. The rise was supported by a significant increase in domestic lithium carbonate futures, with the main contract rising over 6% [8]. New Stock Performance - A new stock, Aisheren, was listed today and saw a remarkable increase of over 200% during trading [12]. The company focuses on medical health, specializing in disposable medical supplies for rehabilitation and medical protection [13]. Hong Kong Market Activity - The Hong Kong market experienced low-level fluctuations, with the stock of Skyworth Group surging over 40% during trading, driven by positive news [2][16].

Core Viewpoint - Aisheren (BJ:920050) was listed on the Beijing Stock Exchange on January 21, with an opening increase of 224.78% and a total market capitalization of 3.49 billion yuan [2] Company Overview - Aisheren specializes in the research, production, and sales of disposable medical consumables used in professional rehabilitation care and medical protection [2] - The company's product range includes rehabilitation care products and surgical infection control products, offering items such as medical care pads, ice bags, surgical gowns, surgical drapes, and surgical kits [2] Financial Performance - Aisheren's total assets increased from approximately 837.99 million yuan in 2022 to about 1.20 billion yuan by June 30, 2025 [3] - Shareholder equity rose from approximately 607.31 million yuan in 2022 to about 795.19 million yuan by June 30, 2025 [3] - The company's revenue for the years 2022 to 2025 (first half) was reported as 574.66 million yuan, 575.00 million yuan, 691.64 million yuan, and 438.20 million yuan respectively [3] - Net profit figures for the same periods were approximately 62.80 million yuan, 66.94 million yuan, 80.61 million yuan, and 49.43 million yuan [3] Future Projections - For the fiscal year 2025, Aisheren expects revenue to be between 890 million yuan and 940 million yuan, representing a year-on-year growth of approximately 28.65% to 35.89% [4] - The projected net profit attributable to shareholders is estimated to be between 89.29 million yuan and 98.48 million yuan, with a growth rate of about 10.63% to 22.01% [4] - The company anticipates that its net profit after deducting non-recurring gains and losses will be between 86.11 million yuan and 95.29 million yuan, reflecting a growth of 19.37% to 32.11% [4] Customer Concentration - Aisheren's top five customers accounted for 81.99% to 88.40% of total sales revenue during the reporting periods, indicating a high level of customer concentration [4] - The largest customer, Medline Group, represented 71.51% to 77.73% of total sales revenue across the same periods [4] Sales Distribution - The majority of Aisheren's revenue comes from international sales, with overseas sales accounting for 90.99% to 96.54% of total revenue during the reporting periods [4] - The company's products are primarily sold in the United States, Europe, and South Korea [4] Ownership Structure - Prior to the IPO, Zhang Yong directly held 1.97% of the company's shares and indirectly controlled 79.58% through the controlling shareholder, Jiangsu Novick [5] - Zhang Yong, who is the chairman and general manager, has a total control of 88.69% of the company's shares [5]

Investment Rating - The investment rating for the company is "Buy," indicating an expected relative increase of over 15% compared to the relevant market index within the next 6-12 months [37]. Core Insights - The company, Aisheren (920050.BJ), specializes in the research, production, and sales of disposable medical consumables in the rehabilitation and medical protection fields. It has established itself as a leading player in the domestic medical dressing industry and has significant competitive advantages in specific segments like medical care pads [2][30]. - The company reported revenues of CNY 574 million in 2022, with a slight growth forecast to CNY 691.6 million in 2024, representing a year-over-year growth of 20.36%. The net profit attributable to the parent company is expected to grow from CNY 63 million in 2022 to CNY 81 million in 2024, with a projected growth rate of 20.54% [8][4]. - The company has a strong partnership with Medline Group, which has been its largest customer since 2007, contributing over 70% of its revenue. This long-term relationship is expected to remain stable [30][31]. Financial Performance - The company achieved revenues of CNY 573.6 million, CNY 574.7 million, and CNY 691.6 million for the years 2022, 2023, and 2024, respectively, with year-over-year growth rates of 0.03%, 0.19%, and 20.36% [4][8]. - The net profit attributable to the parent company for the same years was CNY 62.8 million, CNY 67 million, and CNY 80.7 million, with year-over-year growth rates of -37.12%, 6.62%, and 20.54% [4][8]. Industry Overview - The medical dressing industry is a significant segment of the low-value medical consumables market, accounting for approximately 21%. The global market for medical dressings is projected to grow from USD 9 billion in 2011 to USD 23.5 billion by 2026, driven by increasing demand due to an aging population and rising healthcare expenditures [15][18]. - In China, the medical dressing market is expected to grow from CNY 7 billion in 2011 to CNY 33.3 billion by 2026, indicating a robust growth trajectory supported by improved healthcare infrastructure and rising health awareness among the population [20][18]. Competitive Positioning - Aisheren is positioned among the top ten domestic medical dressing companies and is the largest manufacturer of medical care pads in China. The company differentiates itself through a focus on product research and development, automation in production, and a global supply chain strategy [30][31]. - The company plans to expand its product line to include OTC products and medical collection bags, which are expected to enhance future revenue streams significantly [31][32]. Investment Projects - The company plans to invest CNY 30 million in the construction of a public health medical supplies industrial park, which aims to enhance production capacity and quality control [33][32].

Core Viewpoint - The article emphasizes the importance of disposable medical consumables in modern healthcare, highlighting the leading position of Jiangsu Aisheren Medical Technology Group Co., Ltd. in this sector, driven by innovation and quality manufacturing [1][2]. Group 1: Company Overview - Jiangsu Aisheren was established in 2015, with roots tracing back to 2003, focusing on rehabilitation care and medical infection control [2]. - The company has developed a diverse product matrix, including medical care pads, ice bags, surgical gowns, and surgical kits, serving various healthcare settings [2]. - Aisheren has become one of the top ten exporters of medical dressings in China, with multiple production bases both domestically and internationally [3]. Group 2: Innovation and Competitive Advantage - Aisheren has built a strong competitive edge through process and product innovations, achieving full automation in production processes, which reduces reliance on manual labor and enhances efficiency [2][3]. - The company has upgraded its core products using composite technology, significantly improving physical strength and comfort, with specific products achieving high load capacities and moisture permeability [3]. Group 3: Market Position and Client Relationships - Aisheren has established a robust quality management system and has received multiple international certifications, making it a core supplier for major global brands like Medline and Zarys International Group [4][5]. - The company operates on an ODM/OEM business model, actively participating in product design and development, which strengthens client relationships and enhances product offerings [5]. Group 4: Financial Performance - Aisheren's revenue has shown rapid growth, with 2024 revenue projected at 6.92 billion yuan, a 20.56% increase from the previous year, and a significant rise in net profit [6][8]. - The company’s main business gross margin has remained stable between 22% and 23%, indicating strong cost control and product competitiveness [11]. Group 5: Market Demand and Future Prospects - The global medical dressing market is expected to grow from $9 billion in 2011 to $23.5 billion by 2026, driven by aging populations and increased healthcare standards [13][20]. - Aisheren plans to raise 300 million yuan for expanding production capacity and optimizing its product structure, aiming to enhance its product matrix with high-value items [21][22].

Core Viewpoint - Aishalon (920050.BJ) has initiated its subscription with an issue price of 15.98 CNY per share and a price-to-earnings ratio of 14.99 times, focusing on the medical health sector, particularly in disposable medical consumables for rehabilitation and medical protection [1] Group 1: Company Overview - Aishalon specializes in the research, production, and sales of disposable medical consumables, primarily in rehabilitation care and medical protection [1] - The company operates through ODM/OEM models, providing products for internationally recognized medical device brands [1] - Aishalon's product range includes rehabilitation care products and surgical infection control products, expanding into disinfection, home protection, and emergency protection [1] Group 2: Financial Performance - The company reported revenues of approximately 574 million CNY, 575 million CNY, 692 million CNY, and 438 million CNY for the years 2022, 2023, 2024, and the first half of 2025, respectively [2] - Net profits for the same periods were approximately 62.8 million CNY, 66.9 million CNY, 80.6 million CNY, and 49.4 million CNY [2] - The total assets as of June 30, 2025, were approximately 1.2 billion CNY, with total equity of about 795 million CNY [3] Group 3: Customer Concentration - The top five customers accounted for 81.99%, 86.27%, 86.27%, and 88.40% of total sales revenue over the reporting periods, indicating high customer concentration [2] - The largest customer, Medline Group, represented 71.51%, 73.08%, 71.00%, and 77.73% of sales, significantly impacting the company's financial performance [2]

Group 1 - Shaanxi Tourism officially listed on the Shanghai Stock Exchange, marking the first IPO of 2026, with a first-day increase of 64.10% and a single ticket profit of approximately 26,000 yuan [1] - Next week, two new stocks will be available for subscription: Aisheren, a leading medical dressing company, and Hengyun Chang, a key supplier of semiconductor equipment core components [1][3] - Aisheren specializes in disposable medical consumables for rehabilitation and medical protection, with a strong competitive position in the medical care pad market and stable partnerships with international brands like Medline Group [5][1] Group 2 - Aisheren's forecast for 2025 indicates a net profit of 89.29 million to 98.48 million yuan, representing a year-on-year growth of 10.63% to 22.01% [5][6] - Projected revenue for Aisheren in 2025 is between 889.82 million and 939.87 million yuan, reflecting an increase of 28.65% to 35.89% compared to 2024 [6] - Hengyun Chang is a leading domestic supplier of semiconductor equipment core components, focusing on plasma RF power systems and has achieved mass delivery to major semiconductor equipment manufacturers [1][8] Group 3 - Hengyun Chang's forecast for 2025 shows a net profit of 102 million to 114 million yuan, with a year-on-year decline of 28.21% to 19.54% [8] - Projected revenue for Hengyun Chang in 2025 is estimated to be between 488.99 million and 515.43 million yuan, indicating a decrease of 9.58% to 4.69% compared to 2024 [8] - The company has developed second and third-generation products that support advanced process nodes of 28nm and 7-14nm, respectively, achieving international advanced levels [1]

Investment Rating - The report provides a positive investment rating for the company, indicating it as a hidden champion in the medical care pad and dressing market, with strong ties to leading overseas medical companies [2]. Core Insights - The company, Aishalon, has been deeply engaged in the medical device industry for over 20 years, focusing on the research, production, and sales of disposable medical consumables used in rehabilitation care and medical protection [2][12]. - Aishalon is the largest manufacturer of medical care pads in China and ranks among the top ten exporters of medical dressings, with a rapidly growing sales scale and industry position [2][12]. - The company has established long-term stable partnerships with major clients and has obtained three international certifications, enhancing its market competitiveness [3][17]. Summary by Sections Company Overview - Aishalon specializes in disposable medical consumables, primarily in rehabilitation care and surgical infection control products, and has expanded its product line to include disinfection, home protection, and emergency protection [12]. - The company’s revenue structure is predominantly from overseas sales, with 94.71% of revenue coming from international markets in 2024, primarily from the US and Europe [33][34]. Industry Outlook - The global medical dressing market is projected to reach USD 23.5 billion by 2026, with the medical care pad market growing from CNY 5.08 billion in 2011 to CNY 20.996 billion in 2023 [3]. - The surgical drape market has shown stable growth, with an average annual growth rate of 4.5%, and is expected to continue this trend [3]. Financial Performance - The company anticipates total revenue of CNY 691.64 million in 2024, with a net profit of CNY 80.71 million and a gross margin of 22.91% [2][4]. - For 2025, the projected revenue growth is between 28.65% and 35.89%, with expected revenues ranging from CNY 889.82 million to CNY 939.87 million [2][34]. Competitive Position - Aishalon's core products, such as medical care pads, exhibit superior performance in key competitive indicators compared to peers, with a focus on continuous innovation and product quality [4][12]. - The company has established a robust patent portfolio, with 15 invention patents applied in its main business, contributing to its competitive edge [4][40].

Core Viewpoint - Medline, a major player in the medical supplies industry, successfully went public on NASDAQ with an initial offering price of $29, closing at $41, marking a first-day increase of over 40% and a market capitalization exceeding $66 billion (approximately 464.7 billion RMB) [2] Group 1 - Medline raised $6.26 billion in its IPO, making it the largest IPO globally in 2025 and one of the rare significant projects in the U.S. stock market since Rivian in 2021 [2] - Founded in 1966 by Jon Mills and Jim Mills in Illinois, Medline has focused on providing stable and controllable basic medical supplies to hospitals, including gauze, gloves, surgical gowns, and hospital beds [2] - In 2021, Blackstone, Carlyle, and Hellman & Friedman acquired control of Medline for approximately $34 billion, setting a record for the largest leveraged buyout at that time [2]